Trials / Recruiting
RecruitingNCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Detailed description
This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elranatamab | Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells |
Timeline
- Start date
- 2023-10-03
- Primary completion
- 2032-02-22
- Completion
- 2032-02-22
- First posted
- 2023-09-28
- Last updated
- 2026-04-16
Locations
28 sites across 6 countries: United States, Australia, Canada, China, Japan, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06057402. Inclusion in this directory is not an endorsement.